Literature DB >> 32511765

Whole blood survival motor neuron protein levels correlate with severity of denervation in spinal muscular atrophy.

Christiano R R Alves1, Ren Zhang1, Alec J Johnstone1, Reid Garner1, Eric J Eichelberger1, Salomé Da Silva Duarte Lepez1, Vivian Yi1, Victoria Stevens1, Rebekah Poxson2, Rachel Schwartz2, Phillip Zaworski2, Kathryn J Swoboda1.   

Abstract

INTRODUCTION: We sought to determine whether survival motor neuron (SMN) protein blood levels correlate with denervation and SMN2 copies in spinal muscular atrophy (SMA).
METHODS: Using a mixed-effect model, we tested associations between SMN levels, compound muscle action potential (CMAP), and SMN2 copies in a cohort of 74 patients with SMA. We analyzed a subset of 19 of these patients plus four additional patients who had been treated with received gene therapy to examine SMN trajectories early in life.
RESULTS: Patients with SMA who had lower CMAP values had lower circulating SMN levels (P = .04). Survival motor neuron protein levels were different between patients with two and three SMN2 copies (P < .0001) and between symptomatic and presymptomatic patients (P < .0001), with the highest levels after birth and progressive decline over the first 3 years. Neither nusinersen nor gene therapy clearly altered SMN levels. DISCUSSION: These data provide evidence that whole blood SMN levels correlate with SMN2 copy number and severity of denervation.
© 2020 The Authors. Muscle & Nerve published by Wiley Periodicals LLC.

Entities:  

Keywords:  SMN protein levels; compound muscle action potential; denervation; spinal muscular atrophy; survival motor neuron

Year:  2020        PMID: 32511765     DOI: 10.1002/mus.26995

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  4 in total

1.  Muscle microRNAs in the cerebrospinal fluid predict clinical response to nusinersen therapy in type II and type III spinal muscular atrophy patients.

Authors:  Iddo Magen; Sharon Aharoni; Nancy Sarah Yacovzada; Itay Tokatly Latzer; Christiano R R Alves; Liora Sagi; Aviva Fattal-Valevski; Kathryn J Swoboda; Jacob Katz; Elchanan Bruckheimer; Yoram Nevo; Eran Hornstein
Journal:  Eur J Neurol       Date:  2022-06-07       Impact factor: 6.288

2.  Serum creatine kinase and creatinine in adult spinal muscular atrophy under nusinersen treatment.

Authors:  Maren Freigang; Claudia D Wurster; Tim Hagenacker; Benjamin Stolte; Markus Weiler; Christoph Kamm; Olivia Schreiber-Katz; Alma Osmanovic; Susanne Petri; Alexander Kowski; Thomas Meyer; Jan C Koch; Isabell Cordts; Marcus Deschauer; Paul Lingor; Elisa Aust; Daniel Petzold; Albert C Ludolph; Björn Falkenburger; Andreas Hermann; René Günther
Journal:  Ann Clin Transl Neurol       Date:  2021-03-31       Impact factor: 4.511

3.  Increased systemic HSP70B levels in spinal muscular atrophy infants.

Authors:  Eric J Eichelberger; Christiano R R Alves; Ren Zhang; Marco Petrillo; Patrick Cullen; Wildon Farwell; Jessica A Hurt; John F Staropoli; Kathryn J Swoboda
Journal:  Ann Clin Transl Neurol       Date:  2021-05-15       Impact factor: 4.511

4.  Prognostic Factors and Treatment-Effect Modifiers in Spinal Muscular Atrophy.

Authors:  Giovanni Baranello; Ksenija Gorni; Monica Daigl; Anna Kotzeva; Rachel Evans; Neil Hawkins; David A Scott; Anadi Mahajan; Francesco Muntoni; Laurent Servais
Journal:  Clin Pharmacol Ther       Date:  2021-06-05       Impact factor: 6.903

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.